File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: p63 expression in ovarian tumours: A marker for Brenner tumours but not transitional cell carcinomas

Titlep63 expression in ovarian tumours: A marker for Brenner tumours but not transitional cell carcinomas
Authors
KeywordsBrenner tumour
Ovarian tumours
p63
Transitional cell carcinoma
Issue Date2007
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/HIS
Citation
Histopathology, 2007, v. 51 n. 4, p. 477-483 How to Cite?
AbstractAims: To investigate p63 expression in ovarian neoplasms. Methods and results: Immunohistochemistry using an antibody that detects all p63 isoforms was performed on 103 primary ovarian neoplasms of different histological types. Diffuse nuclear immunoreactivity of p63 was demonstrated in the 17 benign and five borderline Brenner tumours. Only one of the six malignant Brenner tumours displayed p63 expression. p63 immunoreactivity was absent in all the ovarian transitional cell carcinomas (TCC), but was demonstrated extensively in TCCs of the urinary bladder. Besides focal p63 expression in epidermal basal cells of immature and mature teratomas, all other ovarian lesions were devoid of p63 expression. p63 expression was also demonstrated in cervical transitional cell metaplasia and Walthard cell nests of fallopian tubes. Conclusions: Expression of p63 protein is apparently cell lineage specific and in ovarian neoplasms is confined to benign and borderline Brenner tumours. The loss of expression in malignant Benner tumours suggests a role for p63 in Brenner carcinogenesis. The distinct patterns of p63 expression in TCCs in the ovary and urinary bladder may help in their differential diagnosis. © 2007 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/173328
ISSN
2021 Impact Factor: 7.778
2020 SCImago Journal Rankings: 1.626
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLiao, XYen_HK
dc.contributor.authorXue, WCen_HK
dc.contributor.authorShen, DHen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorSiu, MKen_HK
dc.contributor.authorCheung, ANen_HK
dc.date.accessioned2012-10-30T06:29:22Z-
dc.date.available2012-10-30T06:29:22Z-
dc.date.issued2007en_HK
dc.identifier.citationHistopathology, 2007, v. 51 n. 4, p. 477-483en_HK
dc.identifier.issn0309-0167en_HK
dc.identifier.urihttp://hdl.handle.net/10722/173328-
dc.description.abstractAims: To investigate p63 expression in ovarian neoplasms. Methods and results: Immunohistochemistry using an antibody that detects all p63 isoforms was performed on 103 primary ovarian neoplasms of different histological types. Diffuse nuclear immunoreactivity of p63 was demonstrated in the 17 benign and five borderline Brenner tumours. Only one of the six malignant Brenner tumours displayed p63 expression. p63 immunoreactivity was absent in all the ovarian transitional cell carcinomas (TCC), but was demonstrated extensively in TCCs of the urinary bladder. Besides focal p63 expression in epidermal basal cells of immature and mature teratomas, all other ovarian lesions were devoid of p63 expression. p63 expression was also demonstrated in cervical transitional cell metaplasia and Walthard cell nests of fallopian tubes. Conclusions: Expression of p63 protein is apparently cell lineage specific and in ovarian neoplasms is confined to benign and borderline Brenner tumours. The loss of expression in malignant Benner tumours suggests a role for p63 in Brenner carcinogenesis. The distinct patterns of p63 expression in TCCs in the ovary and urinary bladder may help in their differential diagnosis. © 2007 The Authors.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/HISen_HK
dc.relation.ispartofHistopathologyen_HK
dc.subjectBrenner tumouren_HK
dc.subjectOvarian tumoursen_HK
dc.subjectp63en_HK
dc.subjectTransitional cell carcinomaen_HK
dc.subject.meshBrenner Tumor - Diagnosis - Metabolism - Pathologyen_US
dc.subject.meshCarcinoma, Transitional Cell - Diagnosis - Metabolism - Pathologyen_US
dc.subject.meshDiagnosis, Differentialen_US
dc.subject.meshFemaleen_US
dc.subject.meshGene Expression Regulation, Neoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshMembrane Proteins - Genetics - Metabolismen_US
dc.subject.meshOvarian Neoplasms - Diagnosis - Metabolism - Pathologyen_US
dc.subject.meshPrognosisen_US
dc.subject.meshTumor Markers, Biological - Metabolismen_US
dc.titlep63 expression in ovarian tumours: A marker for Brenner tumours but not transitional cell carcinomasen_HK
dc.typeArticleen_HK
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hken_HK
dc.identifier.emailSiu, MK: mkysiu@hkucc.hku.hken_HK
dc.identifier.emailCheung, AN: anycheun@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authoritySiu, MK=rp00275en_HK
dc.identifier.authorityCheung, AN=rp00542en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2559.2007.02804.xen_HK
dc.identifier.pmid17880529-
dc.identifier.scopuseid_2-s2.0-34548861493en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34548861493&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume51en_HK
dc.identifier.issue4en_HK
dc.identifier.spage477en_HK
dc.identifier.epage483en_HK
dc.identifier.isiWOS:000249661900006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLiao, XY=7202134156en_HK
dc.identifier.scopusauthoridXue, WC=26640823700en_HK
dc.identifier.scopusauthoridShen, DH=7401738584en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridSiu, MK=24924018400en_HK
dc.identifier.scopusauthoridCheung, AN=54927484100en_HK
dc.identifier.citeulike1680966-
dc.identifier.issnl0309-0167-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats